NDA 022161 · Astellas
Lexiscan
Regadenoson · Intravenous · Adenosine Receptor Agonist
NovelLast checked: Nov 19, 2026Latest source record: May 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Apr 10, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
66
8 Phase 3, 7 recruiting
FAERS reports
4,773
2,655 serious, 130 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 28, 2024.
LEXISCAN® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 17, 2017 Supplement 13 · Efficacy LabelLetter
- Apr 10, 2008 Original approval · Type 1 - New Molecular Entity NovelLabelReviewOther Important Information from FDA
1 products under this application
- LEXISCAN · REGADENOSON 0.4MG/5ML (0.08MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Regadenoson" as an intervention, any sponsor and status, largest first.
- Prognostic Value of Oxygen-15 Water PET in Coronary Artery DiseasePivotal-lookingRecruiting
Vastra Gotaland RegionGovernment (non-federal)
NCT07932314 · 40,000 participants (planned) · Start Dec 2026 · Primary completion Dec 2036
Drug: Oxygen-15 Water · For: Coronary Artery Disease; Microvascular Coronary Artery Disease; Microvascular Coronary Dysfunction
Sites: Gothenburg, Sweden
- ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00208299 · 1,231 participants · Start Oct 2003 · Primary completion Aug 2006
Drug: Regadenoson; Adenosine · For: Coronary Artery Disease
Sites: Palo Alto, California
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT01618669 · 1,147 participants · Start Jun 2012 · Primary completion Dec 2014
Drug: Regadenoson · For: Coronary Artery Disease (CAD)
Sites: Mobile, Alabama; Fremont, California; Long Beach, California · 69 sites in all
- A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00862641 · 1,009 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: Regadenoson; Placebo · For: Asthma; Coronary Artery Disease; Pulmonary Disease, Chronic Obstructive
Sites: Montgomery, Alabama; Anaheim, California; Encinitas, California · 48 sites in all
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States StudyPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06854458 · 1,000 participants (planned) · Start Jun 27, 2025 · Primary completion Jan 2029
Drug: Gadavist; Vasodilator · For: Ischemic Heart Disease (IHD); Cardiac Magnetic Resonance Imaging; Myocardial Blood Flow
Sites: San Francisco, California; Louisville, Kentucky; Boston, Massachusetts · 13 sites in all
- ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00208312 · 787 participants · Start Apr 2004 · Primary completion Jun 2005
Drug: Regadenoson; Adenosine · For: Coronary Artery Disease
Sites: Palo Alto, California
- An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)Pivotal-lookingCompleted
GE HealthcareIndustry
NCT03354273 · 730 participants · Start Jun 5, 2018 · Primary completion May 5, 2022
Drug: PET MPI; SPECT MPI and 1 more · For: Coronary Artery Disease (CAD)
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 53 sites in all
- A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal ImpairmentPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00863707 · 511 participants · Start Apr 2009 · Primary completion Dec 2009
Drug: Regadenoson; Placebo · For: Kidney Diseases; Coronary Artery Disease
Sites: Anniston, Alabama; Little Rock, Arkansas; Bell Gardens, California · 41 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea511
- dyspnoea409
- injection site extravasation361
- vomiting358
- headache328
- hypotension315
- cardiac arrest284
- dizziness276
- seizure256
- chest pain233
- blood pressure decreased208
- bradycardia196
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 144 |
| 2009 | 104 |
| 2010 | 76 |
| 2011 | 55 |
| 2012 | 425 |
| 2013 | 514 |
| 2014 | 473 |
| 2015 | 301 |
| 2016 | 380 |
| 2017 | 418 |
| 2018 | 424 |
| 2019 | 315 |
| 2020 | 250 |
| 2021 | 175 |
| 2022 | 209 |
| 2023 | 188 |
| 2024 | 155 |
| 2025 | 103 |
| 2026 | 64 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Lexiscan* (Regadenoson*) · HCPCS J2785
2024 spending
$15.3M
Beneficiaries
563,958
568,842 claims
Per beneficiary
$27
2024 ASP limit $6.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $121,070,244 |
| 2021 | $131,961,556 |
| 2022 | $131,026,259 |
| 2023 | $118,734,034 |
| 2024 | $15,267,151 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Stress Perfusion Cardiac Magnetic Resonance vs SPECT Imaging for Detection of Coronary Artery Disease.
Arai AE, Schulz-Menger J, Shah DJ, et al. · J Am Coll Cardiol 2023 · Clinical Trial, Phase III, Multicenter Study
- The Effect of Monitored Walking on Extracardiac Intestinal Activity in Myocardial Perfusion Imaging.
Strok A, Dolenc Novak M, Guzic Salobir B, et al. · J Nucl Med Technol 2024 · Randomized Controlled Trial
- Adenosine A2A receptor agonist (regadenoson) in human lung transplantation.
Lau CL, Beller JP, Boys JA, et al. · J Heart Lung Transplant 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
- Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy.
Roldan P, Ravi S, Hodovan J, et al. · Cardiovasc Ultrasound 2022 · Clinical Trial
- Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease.
Lindner JR, Belcik T, Widlansky M, et al. · PLoS One 2019 · Clinical Trial, Multicenter Study
- A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients.
Drakos S, Chatzantonis G, Bietenbeck M, et al. · Sci Rep 2021 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.